APOP Cellect Biotechnology Ltd

Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

On March 24, the Company announced a strategic merger agreement with privately held Quoin Pharmaceuticals, a U.S. based specialty pharmaceutical company focused on rare and orphan diseases. Under the terms of the merger agreement, Quoin has secured $25 million in committed funding from a highly regarded, institutional healthcare investor. Current Cellect shareholders will retain approximately 25% of the combined shares before investment. The merger is expected to close by the end of the second quarter of 2021. Cellect has also signed an agreement to sell its wholly-owned subsidiary company, Cellect Biotherapeutics, to EnCellX, Inc. - a newly founded biotechnology company based in San-Diego, CA. - to continue the development of Cellect’s products.

Recent Clinical Highlights

• Due to the COVID-19 pandemic and the Company decision to shift attention and resources to the U.S. Phase I clinical trial, which is expected to enroll the first patient soon, the Company has elected to close the Phase 1/2 clinical trial being performed in Israel earlier than expected, since recruitment of the 12th and final patient was not assured in a timely manner.
• To date, Data from the open label Israel Phase 1/2 clinical trial supports the Company’s optimism as it extends its clinical program to the U.S. The Company expects to publish the top line results of the Israel trial in Q2.

“Concurrent with our plans to seek strategic alternatives to maximize shareholder value, we also remained focus on advancing our clinical interests in the U.S.,” commented Dr. Shai Yarkoni, Chief Executive Officer. “We have signed a compelling business proposition with Quoin and a privately-held U.S. biotechnology company that allows our current shareholders to benefit from Quoin’s promising technology and the fruits of continued progress of our clinical programs as they reach critical inflections points through the issuance of contingent value rights to our shareholders in connection with the sale of Cellect Biotherapeutics.”

Fourth Quarter and Full Year 2020 Financial Results:

• Research and development (R&D) expenses for the fourth quarter and for the full year of 2020 were $0.53 million and $1.83 million respectively, compared to $0.80 million in the fourth quarter of 2019 and $3.77 million for the full year of 2019. The decrease in R&D expenses for the full year of 2020 as compared to the full year of 2019 resulted from the reduction in our research and development activities, as we decreased the number of our employees engaged in research and related activities.
• General and administrative (G&A) expenses for the fourth quarter and for the full year of 2020 were $0.67 million and $2.52 million respectively, compared to $0.74 million in the fourth quarter of 2019 and $3.18 million for the full year of 2019. The decrease in G&A expenses for the full year of 2020 as compared to the full year of 2019 resulted from the reduction in the company activities resulting from a decrease in the number of employees.
• Finance expenses for the fourth quarter of 2020 were $0.38 million, and financial expenses were $1.27 million for the full year of 2020, compared to finance expenses of $0.35 million in the fourth quarter of 2019 and financial income of $1.72 million for the full year of 2019, respectively. The financial expenses in the full year of 2020 as compared to the financial income in the full year of 2019 is primarily due to the change in the fair value of the listed warrants granted in our U.S. initial public offering in 2016 and of the unregistered warrants granted in our registered direct offerings in 2019.
• Total Comprehensive loss for the fourth quarter and for the full year of 2020 was $1.58 million and $5.62 million respectively, or $0.004 per share for the fourth quarter and $0.015 per share for the full year of 2020, respectively, compared to $1.89 million, or $0.008 per share, in the fourth quarter of 2019 and $5.23 million, or $0.025 per share, for the full year of 2019.

* For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on December 31, 2020 (U.S. $1 = NIS 3.215).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of cell-based therapies.

The Company’s technology is expected to provide researchers, clinicians and pharmaceutical companies with the tools to rapidly isolate specific cells in quantity and quality, allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company’s history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company’s ability to continue as a going concern; or maintain its current operations; uncertainties involving any strategic transaction the Company may decide to enter into as the result of its current efforts to explore new strategic alternatives; uncertainties of cash flows and inability to meet working capital needs; the Company’s ability to obtain regulatory approvals; the Company’s ability to obtain favorable pre-clinical and clinical trial results; the Company’s technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company’s clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company’s industry; unforeseen scientific difficulties may develop with the Company’s technology; and the Company’s ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in Cellect Biotechnology Ltd.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC’s website, www.sec.gov, and in the Company’s periodic filings with the SEC.

ContactCellect Biotechnology Ltd.Eyal Leibovitz, Chief Financial Officerwww.cellect.co+972-9-974-1444

Or

EVC Group LLCMichael Polyviou(732) 933-2754mpolyviou@evcgroup.com

Cellect Biotechnology LtdConsolidated Statement of Operation

		Convenience
		translation
		Twelve months ended				Twelve months ended								Three months ended
		December 31,				December 31,								December 31,
		2020				2020				2019				2020				2019
		Unaudited				Audited				Audited				Unaudited				Unaudited
		U.S. dollars				NIS
		(In thousands, except share and per share data)
Research and development expenses			1,830				5,883				12,122				1,693				2,571
General and administrative expenses			2,523				8,111				10,210				2,167				2,378
Operating loss			4,353				13,994				22,332				3,860				4,949
Financial expenses (income) due to warrants exercisable into ADS			846				2,721				(7,022	)			4				998
Other financial expenses (income), net			424				1,362				1,498				1,224				129
Total comprehensive loss			5,623				18,077				16,808				5,088				6,076
Loss per share:
Basic and diluted loss per share			0.015				0.049				0.079				0.013				0.027
Weighted average number of shares outstanding used to compute basic and diluted loss per share			368,078,786				368,078,786				212,642,505				390,949,079				224,087,799

Cellect Biotechnology LtdConsolidated Balance Sheet Data

		Convenience
		translation
		December 31,				December 31,				December 31,
		2020				2020				2019
		Unaudited				Audited				Audited
		U.S. dollars				NIS
ASSETS		(In thousands, except share and per share data)
CURRENT ASSETS:
Cash and cash equivalents			5,277				16,964				18,106
Other receivables			88				284				469
			5,365				17,248				18,575
NON-CURRENT ASSETS:
Restricted cash			100				322				328
Right of use - Assets under operating lease			219				705				1,035
Other long-term assets			22				72				94
Property, plant and equipment, net			384				1,232				1,288
			725				2,331				2,745
			6,090				19,579				21,320
LIABILITIES ANDSHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables			121				389				158
Leases liabilities			115				369				396
Other payables			693				2,228				3,080
			929				2,986				3,634
NON-CURRENT LIABILITIES:
Warrants to ADS			380				1,222				2,172
Leases liabilities			122				391				677
			502				1,613				2,849
EQUITY:
Ordinary shares of no par value:
Authorized: 500,000,000 shares at December 31, 2019 and December 31 2020; Issued and outstanding: 224,087,799*) and 390,949,079*) shares as of December 31, 2019 and December 31, 2020, respectively.			-				-				-
Additional Paid In Capital			39,452				126,838				108,598
Share-based payments			5,135				16,508				16,528
Treasury shares			(2,932	)			(9,425	)			(9,425	)
Accumulated deficit			(36,996	)			(118,941	)			(100,864	)
			4,659				14,980				14,837
			6,090				19,579				21,320

*)

Net of 2,641,693 treasury shares of the Company held by the Company.

Cellect Biotechnology LtdConsolidated Cash Flow Data

		Convenience
		translation
		Twelve months ended				Twelve months ended								Three months ended
		December 31,				December 31,								December 31,
		2020				2020				2019				2020				2019
		Unaudited				Audited				Audited				Unaudited				Unaudited
		U.S. dollars				NIS
						(In thousands)
Cash flows from operating activities:
Total comprehensive loss			(5,623	)			(18,077	)			(16,808	)			(5,088	)			(6,076	)
Adjustments to reconcile net loss to net cash used in operating activities:
Exchange rate difference			(412	)			(1,326	)			1,036				(1,115	)			(50	)
Loss (gain) from revaluation of financial assets presented at fair value through profit and loss			-				-				-				-				(8	)
Depreciation of Right of use - Assets under operating lease			115				369				433				97				(24	)
Depreciation			109				350				373				94				88
Finance expenses			27				88				128				40				128
Issuance expenses			-				-				1,621				-				1,621
Changes in fair value of traded and non traded warrants to ADS			847				2,722				(8,643	)			4				708
Share-based payment			229				738				2,708				262				807
Decrease (increase) in other receivables			65				207				385				417				239
Increase (decrease) in other payables			(193	)			(621	)			(1,663	)			528				192
Interest received			20				64				93				8				168
Net cash used in operating activities			(4,816	)			(15,486	)			(20,337	)			(4,753	)			(2,207	)
Cash flows from investing activities:
Restricted deposit, net			2				6				9				7				9
Proceeds received from the sale of fixed assets			11				35				6				-				6
(Purchase) Sales of marketable securities measured at fair value through profit and loss			-				-				-				-				-
Purchase of property, plant and equipment			(103	)			(329	)			(123	)			(170	)			(3	)
Net cash provided by investing activities			(90	)			(288	)			(108	)			(163	)			12
Cash flows from financing activities:
Exercise of warrants and stock options into shares			1,435				4,615				-				-				-
Repayment on account of lease liabilities			(137	)			(441	)			(522	)			(117	)			(101	)
Issue of share capital and warrants, net of issue costs			2,860				9,194				22,393				-				(1,330	)
Net cash provided (used) by financing activities			4,158				13,368				21,871				(117	)			(1,431	)
Exchange differences on balances of cash and cash equivalents			393				1,264				(1,129	)			1,108				(117	)
Increase (decrease) in cash and cash equivalents			(355	)			(1,142	)			297				(3,925	)			(3,743	)
Balance of cash and cash equivalents at the beginning of the period			5,632				18,106				17,809				20,889				21,849
Balance of cash and cash equivalents at the end of the period			5,277				16,964				18,106				16,964				18,106